Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.54 |
| ▸ | AGXT | P21549 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 7/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | CMA1 | P23946 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17219243 | 1.00 | IDO1 (0.54) | IDO1AGXTMAOBTAAR1CHRM2 | |
| SCHEMBL14748298 | 0.84 | IDO1 (0.57) | IDO1AGXTMAOBTAAR1CHRM2 | |
| SCHEMBL17219246 | 0.84 | CHRM2 (0.47) | MAOBCHRM2CHRM1CHRM3 | |
| SCHEMBL9945423 | 0.81 | IDO1 (0.54) | IDO1AGXTMAOBTAAR1CHRM2 | |
| SCHEMBL17218393 | 0.81 | IDO1 (0.54) | IDO1AGXTMAOBTAAR1CHRM2 | |
| SCHEMBL17217193 | 0.81 | KIF11 (0.36) | IDO1AGXT | |
| SCHEMBL17217545 | 0.81 | IDO1 (0.51) | IDO1MAOBTAAR1 | |
| SCHEMBL17219637 | 0.81 | CYP3A4 (0.51) | IDO1AGXTMAOBTAAR1 | |
| SCHEMBL17216444 | 0.80 | IDO1 (0.48) | IDO1AGXTMAOBTAAR1 | |
| SCHEMBL17219072 | 0.80 | IDO1 (0.53) | IDO1AGXTMAOBTAAR1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772290-B2 | Alpha-arylmethoxyacrylate derivative, preparation method thereof, and pharmaceutical composition containing same | Oscotech Inc. (KR) | 2014-07-08 | — | — | US | disclosed |
| US-20120149707-A1 | ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | OSCOTEC INC. (KR) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149707-A1 | ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | HIF1A, HIF1AN, EGLN3 | IDO1 1515/4885AGXT 1291/4885MAOB 2441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.